Biogen Says Fed. Circ. Patent Ax Ruling 'Breaks New Ground'
Biogen asked the full Federal Circuit on Wednesday to revisit a panel decision that revived a jury verdict invalidating claims of a patent covering Biogen's blockbuster multiple sclerosis treatment Avonex, saying...To view the full article, register now.
Already a subscriber? Click here to view full article